Except in the melanoma-PRJEB23709 cohort, the actual response rates to anti-PD1 therapy in the C2 and C3 groups were much lower than in the C1 group, consistent with our results (Figures 4G; 6A–D). The gene discussed is PDCD1; the disease is melanoma.